Soligenix’s (SNGX) dusquetide, a treatment of Behcet’s disease , received FDA orphan designation, according to a post to the agency’s website.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX: